Peter Ho

He received his B.A. in biology from The Johns Hopkins University and his M.D. and Ph.D. in pharmacology from Yale University, then completed a pediatrics residency at Boston Children’s Hospital, followed by clinical fellowships in pediatric hematology/oncology at the Dana-Farber Cancer Institute and in clinical oncology and regulatory sciences jointly through the FDA and the National Cancer Institute. He began his career in drug discovery and development at the investigational drug branch of NCI’s Cancer Therapy Evaluation Program, followed by positions of increasing responsibility at Novartis and DuPont Pharmaceuticals. He subsequently served as Senior VP of the Oncology Center of Excellence in Drug Discovery at GlaxoSmithKline and as VP of Oncology Clinical Development at Johnson & Johnson. He was Co-Founder and President of BeiGene Ltd. and most recently served as the Chief Medical Officer for Epizyme Inc.

Since 1995, he has been directly responsible for first-time-in-human dosing of 18 anticancer agents and has overseen the development of over 60 compounds in all phases of clinical trials.This work has contributed to 10 NCE or biologics approvals to date: Gleevec®; Arranon®; Tykerb®; Promacta®; Votrient®, Synribo®; Tafinlar®; Mekinist®; Sylvant®; and Rydapt®. He is a member of the pediatric cancer working group of the Cancer Moonshot Task Force.